AT13387: Phase I/II started

Astex began the open-label Phase I/II AT13387-04 trial to evaluate AT13387 in up to 164 CRPC patients who have progressed after treatment with Zytiga abiraterone and steroids. The Phase I portion will evaluate 2 doses of AT13387 plus abiraterone acetate and steroids in up to 52 patients to determine the dose to be used in the Phase II portion, which will compare AT13387 plus abiraterone acetate vs. abiraterone acetate alone in up to 112 patients. ...